{
    "clinical_study": {
        "@rank": "99201", 
        "arm_group": [
            {
                "arm_group_label": "Treated Group", 
                "arm_group_type": "Experimental", 
                "description": "Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month."
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The study objectives are to evaluate Tonsitin\u2122 (10% Lactic Acid) safety, tolerability and\n      preliminary efficacy, as a potent treatment for Recurrent Tonsillitis in children."
        }, 
        "brief_title": "A Phase I/II to Assess Safety, Tolerability and Efficacy of DL-lactic Acid Syrup in Children With Recurrent Tonsillitis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Tonsillitis in Children", 
        "condition_browse": {
            "mesh_term": "Tonsillitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children at the ages of 5-16.\n\n          -  Patient is suffering from recurrent documented sore throat with at least 4\n             tonsillitis episodes during the preceding year (at least one verified by culture or\n             rapid antigen testing for Streptococcus A).\n\n          -  Patient with clinical presentation of irregular tonsils.\n\n          -  Tonsils size graded between 2.5-4.\n\n          -  Clinical diagnosis of bacterial known in recurrent pharyngeal-tonsillitis.\n\n          -  Patient is willing to participate in the study and adhere to the study protocol\n\n          -  Patient's guardian and/or Patient have signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Clinical diagnosis of acute tonsillitis/pharyngitis caused by Streptococcus pyogenes\n             (Positive RSAT or microbial culture).\n\n          -  Subjects who are known as Streptococcus pyogenes carriers\n\n          -  Subject's requiring any other medication (topical or systemic) that may affect the\n             course of the disease during the study period (e.g. antibiotics, sedating\n             antihistamines), and/or did not completed 14 days from end of antibiotics treatment.\n\n          -  Subjects with known hypersensitivity to lactose.\n\n          -  Subject is suffering from peritonsillar abscess.\n\n          -  Subject suffers from an active peptic ulcer\n\n          -  Subjects who are suffering from any concomitant disease which in the judgment of the\n             investigator will interfere with the conduct or interpretation of the study results.\n\n          -  Subject is currently participating in another clinical study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01988558", 
            "org_study_id": "LA-001-IL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treated Group", 
                "description": "Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)", 
                "intervention_name": "DL - Lactic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "description": "Placebo group to receive Raspberry flavored Syrup", 
                "intervention_name": "Raspberry flavored syrup", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Recurrent Tonsillitis", 
            "Streptococcus A"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tzrifin", 
                    "country": "Israel"
                }, 
                "name": "Assaf Harofeh Medical Center"
            }, 
            "investigator": {
                "last_name": "Mati Berkovitz, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/II, Randomized, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of DL-lactic Acid Syrup (Tonsitin) in Children With Recurrent Tonsillitis.", 
        "other_outcome": {
            "measure": "QOL Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "Chnge from baseline at 90 days post treatment"
        }, 
        "overall_contact": {
            "email": "moshe@brd.co.il", 
            "last_name": "Moshe T Neuman, PhD", 
            "phone": "972-8-9366700", 
            "phone_ext": "0"
        }, 
        "overall_official": {
            "affiliation": "MOH", 
            "last_name": "Mati Berkovitz, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety evaluation - Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "At 90 days post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01988558"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tonsil Size", 
                "safety_issue": "No", 
                "time_frame": "Chnge from baseline at 6 months post treatment"
            }, 
            {
                "measure": "Number of Tonsillitis episodes", 
                "safety_issue": "No", 
                "time_frame": "Chnge in medical history number of recurrent Tonsillitis episodes within 6 months post treatment"
            }
        ], 
        "source": "Yali Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yali Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}